



## Alset International Limited Receives Bonus Shares of Impact Biomedical Inc from its investment in DSS, Inc.

**SINGAPORE, 31 August 2023** – Singapore Exchange-listed Alset International Limited (SGX Stock Code: 40V) (“**AI**”, the “**Company**” or together with its subsidiaries, the “**Group**”) wishes to update our shareholders that both the Group and Alset Inc. (NASDAQ: AEI), the indirect parent company of AI, have collectively received a total of 251,249,056 Impact Biomedical Inc’s shares, of which 110,395,392 Impact Biomedical Inc’s shares (“**Bonus Shares**”) are attributable to the Group as part of a stock dividend distributed by our investment company, DSS Inc. (Nasdaq: DSS) (“**DSS**”). Impact Biomedical Inc. was a wholly owned subsidiary of DSS prior to the issuance of the bonus shares.

The Bonus Shares are part of the intention of management and board of directors of DSS to take Impact Biomedical Inc. public and to reward the DSS shareholders via the issuance of Impact Biomedical Inc. shares. Impact Biomedical Inc. is currently in the midst of preparing its registration statement (Form S-1) for the purpose of an initial public offering.

Impact Biomedical Inc. is an emerging human healthcare company. Impact BioMedical Inc. strives to leverage its scientific know-how and intellectual property rights to provide solutions plaguing the biomedical field for decades, and pledges efforts in R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno-related diseases. Their products pipeline includes Linebacker, Laetose™, Functional Fragrance Formulation (“**3F™**”) and Equivir. Shareholders may wish to refer to our circular to shareholders dated 4 June 2020, for more details on the technology and application of the aforementioned products.

As illustrated in Impact Biomedical Inc. registration statement (Form S-1) pertaining to the Bonus Shares dated 1 August 2023, Impact Biomedical Inc. have three additional products, VanXin, Quantum, and CRST1, which the management of Impact Biomedical Inc. believes to have “high potentiality of viability and commercialisation”. The following information on the additional products has been extracted from the abovementioned S-1 for your easy reference: “*VanXin is a natural food preservative booster made up of natural occurring compounds, that can extend the shelf life of various products. Quantum, our Patent Cliff solution, uses advanced methods to modify natural compounds and existing drugs, while maintaining the safety attributes of the original molecules. CRST 1 is our advanced adjuvant for next generation vaccine applications.*”

Impact Biomedical Inc.(together with its subsidiaries, the “**Impact Group**”) has licensed the technology and development of Linebacker and Equivir to ProPhase Labs (NASDAQ: PRPH) and separately, obtained a patent through Global BioLife, Inc., a division of the Company’s wholly owned subsidiary Impact BioMedical Inc. from China National Intellectual Property Administration for 3F™ technology that is effective as a mosquito repellent through a fragrant compound derived from botanical oils.

### End of Press Release ###

### About Impact BioMedical, Inc.

Impact Biomedical Inc. is an emerging human healthcare company. Impact BioMedical Inc. strives to leverage its scientific know-how and intellectual property rights to provide solutions plaguing the biomedical field for decades, and pledges effort in R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno-related diseases.

Website: <https://www.impactbiomedinc.com/>



### **About Alset International Limited**

Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Alset International Limited operates as a global enterprise involved in (i) property development and related services; (ii) biomedical and direct sales businesses; (iii) investment activities; and (iv) food and beverage.

For more information, please visit: [www.asetinternational.com](http://www.asetinternational.com)

---

*This Press Release has been reviewed by the Company's Sponsor, Hong Leong Finance Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this Press Release, including the correctness of any of the statements or opinions made or reports contained in this Press Release.*

*The contact person for the Sponsor is Ms Vera Leong, Vice President, Hong Leong Finance Limited, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581, telephone (+65) 6415 9881.*